Schonfeld Strategic Advisors LLC Pharma Cyte Biotech, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$14 Billion
Q1 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 23,500 shares of PMCB stock, worth $48,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,500

Previous 23,200 1.29%

Holding current value

$48,410

Previous $50,000 10.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.95 - $2.48 $585 - $744	300 Added 1.29%	23,500 $55,000
Q4 2023 Feb 14, 2024	SELL	$2.01 - $2.34 $200 - $234	-100 Reduced 0.43%	23,200 $50,000
Q3 2023 Nov 14, 2023	SELL	$2.09 - $2.89 $418 - $578	-200 Reduced 0.85%	23,300 $48,000
Q2 2023 Aug 14, 2023	SELL	$2.74 - $3.18 $1,370 - $1,590	-500 Reduced 2.08%	23,500 $67,000
Q1 2023 May 15, 2023	SELL	$2.83 - $3.03 $3,396 - $3,635	-1,200 Reduced 4.76%	24,000 $69,000

Q4 2022 Feb 14, 2023	BUY	$2.72 - $3.07 $1,088 - $1,228	400 Added 1.61%	25,200 $73,000
Q3 2022 Nov 14, 2022	SELL	$2.24 - $2.85 $3,136 - $3,990	-1,400 Reduced 5.34%	24,800 $60,000
Q2 2022 Aug 15, 2022	SELL	$1.99 - $2.33 $199 - $233	-100 Reduced 0.38%	26,200 $59,000
Q1 2022 May 16, 2022	SELL	$1.91 - $2.77 $7,831 - $11,357	-4,100 Reduced 13.49%	26,300 $60,000
Q4 2021 Feb 14, 2022	SELL	$2.4 - $3.19 $138,720 - $184,382	-57,800 Reduced 65.53%	30,400 $76,000
Q3 2021 Nov 16, 2021	BUY	$2.28 - $16.9 $201,095 - $1.49 Million	88,200 New	88,200 $280,000

Others Institutions Holding PMCB

# of Institutions

Shares Held

1.07M

Call Options Held

5.4K

Put Options Held

400

View Full List

About PharmaCyte Biotech, Inc.

Ticker PMCB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,750,100
Market Cap $42.7M
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...

More about PMCB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Pharma Cyte Biotech, Inc. Transaction History